Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cytochroma has granted an exclusive license to Mitsubishi Tanabe Pharma in the US and Asia, including Japan, to develop and commercialize CTA018, its novel vitamin D analog, as part of an agreement.
Subscribe to our email newsletter
Under the terms of the agreement, Cytochroma has granted Mitsubishi Tanabe Pharma (MTPC) an exclusive license to develop, manufacture and commercialize CTA018 in the US and Asia. Cytochroma may receive up to a total of C$105 million, which includes an upfront payment, milestone payments, and an equity investment.
In exchange for the equity investment, MTPC will receive a certain number of Cytochroma’s class C shares. The MTPC and Cytochroma will jointly develop and commercialize CTA018 in the US. In Asia, including Japan, MTPC has full rights and responsibilities for product development, approval, and commercialization of CTA018, and will pay Cytochroma a royalty on sales.
The agreement also grants MTPC access to certain follow-on compounds to CTA018 for the same territories, with Cytochroma retaining all rights to CTA018 and these follow-on compounds in all regions outside the US and Asia.
CTA018 is entering Phase II development in Canada for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD).
Charles Bishop, president and CEO of Cytochroma, said: “The formation of this partnership is a landmark event for Cytochroma and represents an important validation of our novel approach to treating secondary hyperparathyroidism in CKD patients.”